MaxCyte,
Inc.
("MaxCyte" or the "Company")
Exercise of options and PDMR
dealing
ROCKVILLE, MD, August 29, 2024: MaxCyte Inc., (NASDAQ: MXCT; LSE: MXCT), a leading,
cell-engineering focused company providing enabling platform
technologies to advance the discovery, development, and
commercialization of next-generation cell therapeutics and to
support innovative, cell-based research, announces that on 26
August 2024, as per a filing lodged with the U.S. Securities and
Exchange Commission, John Johnston, a Non-Executive Director of the Company,
exercised options over 3,000 shares of common stock
of $0.01 of the Company ("Common Stock") ("Exercise") in
aggregate. The 3,000 new shares of Common Stock were issued
pursuant to the Company's existing its block admission
facility and were sold by John Johnston at a price range
between $4.230 and $4.350 per Common Stock ("Sale").
The sold shares represent approximately 0.9% of John
Johnston's total equity and option holdings in the Company's
stock capital, respectively.
Following the Exercise and
Sale, John Johnston holds 120,583 shares of Common Stock
representing 0.1% of the issued stock capital of the Company.
Following the Exercise, John Johnston holds a further 186,918
options over Common Stock and 21,367 restricted stock
units.
The sales and option exercises were
effected pursuant to a Rule 10b5-1 trading plan adopted by John
Johnston on 19 December 2023 relating solely to the sale of shares
acquired from exercise of options that expire on 14 July
2027.
MaxCyte Contacts:
|
US IR
Adviser
Gilmartin
Group
David
Deuchler, CFA
|
+1 415-937-5400
ir@maxcyte.com
|
|
Nominated Adviser and Joint
Corporate Broker
Panmure
Gordon
Emma Earl /
Freddy Crossley
Corporate
Broking
Rupert
Dearden
|
+44 (0)20 7886 2500
|
|
UK IR
Adviser
ICR
Consilium
Mary-Jane
Elliott
Chris
Welsh
|
+44 (0)203 709 5700
maxcyte@consilium-comms.com
|
About MaxCyte
At MaxCyte, we pursue cell
engineering excellence to maximize the potential of cells to
improve patients' lives. We have spent more than 20 years honing
our expertise by building best-in-class platforms, perfecting the
art of the transfection workflow, and venturing beyond today's
processes to innovate tomorrow's solutions. Our ExPERT™ platform,
which is based on our Flow Electroporation® technology, has been
designed to support the rapidly expanding cell therapy market and
can be utilized across the continuum of the high-growth cell
therapy sector, from discovery and development through
commercialization of next-generation, cell-based medicines. The
ExPERT family of products includes: four instruments, the ATx™,
STx™, GTx™ and VLx™; a portfolio of proprietary related processing
assemblies or disposables; and software protocols, all supported by
a robust worldwide intellectual property portfolio. By providing
our partners with the right technology platform, as well as
scientific, technical, and regulatory support, we aim to guide them
on their journey to transform human health. Learn
more at maxcyte.com and
follow us on X (formerly Twitter) and LinkedIn.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS
DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY
ASSOCIATED WITH THEM
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
John Johnston
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Non-Executive Director
|
|
b)
|
Initial notification
/Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
MaxCyte, Inc.
|
|
b)
|
LEI
|
54930053YHXULRFCU991
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
|
Common Stock of $0.01 each
|
|
|
|
|
Identification code
|
US57777K1060
|
|
|
|
|
b)
|
Nature of the transaction
|
Exercise of Options over
common stock
|
|
c)
|
Price(s) and volume(s)
|
|
|
|
|
|
|
|
Exercise Price(s)
|
Volume(s)
|
|
|
|
|
$2.926
|
3,000
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information
|
|
|
|
|
|
- Aggregated volume
|
3,000
|
|
|
|
|
- Price
|
$2.926
|
|
|
|
|
e)
|
Date of the transaction
|
26 August 2024
|
|
f)
|
Place of the transaction
|
US Stock Exchange, Nasdaq
|
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
John Johnston
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Non-Executive Director
|
|
b)
|
Initial notification
/Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
MaxCyte, Inc.
|
|
b)
|
LEI
|
54930053YHXULRFCU991
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
|
Common Stock of $0.01 each
|
|
|
|
|
Identification code
|
US57777K1060
|
|
|
|
|
b)
|
Nature of the transaction
|
Sale of common stock
|
|
c)
|
Price(s) and volume(s)
|
|
|
|
|
|
|
|
Exercise Price(s)
|
Volume(s)
|
|
|
|
|
$4.2300
|
400
|
|
|
|
|
$4.2500
|
300
|
|
|
|
|
$4.2550
|
400
|
|
|
|
|
$4.2650
|
58
|
|
|
|
|
$4.2700
|
301
|
|
|
|
|
$4.2800
|
152
|
|
|
|
|
$4.2900
|
87
|
|
|
|
|
$4.3000
|
600
|
|
|
|
|
$4.3100
|
296
|
|
|
|
|
$4.3200
|
206
|
|
|
|
|
$4.3500
|
200
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information
|
|
|
|
|
|
- Aggregated volume
|
3,000
|
|
|
|
|
- Price
|
$4.2804
|
|
|
|
|
e)
|
Date of the transaction
|
26 August 2024
|
|
f)
|
Place of the transaction
|
US Stock Exchange, Nasdaq
|